Patients in pediatric phase I and early phase II clinical oncology trials at gustave roussy: A 13-year center experience

Journal of Pediatric Hematology/Oncology

Volumn 37, Issue 2, 2015, Pages e102-e110

  Bautista, Francisco ^a   Di Giannatale, Angela ^a   Dias Gastellier, Nathalie ^a   Fahd, Mony ^a   Valteau Couanet, Domineque ^a   Couanet, Dominique ^a   Grill, Jacques ^a   Brugières, Laurence ^a   Dufour, Christelle ^a   Gaspar, Nathalie ^a   Minard Colin, Veronique ^a   Kalifa, Chantal ^a   Oberlin, Odile ^a   Patte, Catherine ^a   Vassal, Gilles ^a   Geoerger, Birgit ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

early drug development; outcome; pediatric oncology; toxicity

Indexed keywords

CILENGITIDE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DALOTUZUMAB; DAUNORUBICIN; DEHYDRODIDEMNIN B; DOXORUBICIN; ERLOTINIB; FIGITUMUMAB; GEMCITABINE; IMATINIB; IRINOTECAN; NAVELBINE; OXALIPLATIN; R 1507; RAPAMYCIN; RIDAFOROLIMUS; ROBATUMUMAB; SONIDEGIB; TEMOZOLOMIDE; TEMSIROLIMUS; TOPOTECAN; VINCRISTINE;

ARTICLE; BRAIN TUMOR; CANCER RECURRENCE; CHILD; CHILDHOOD CANCER; EWING SARCOMA; FEMALE; GLIOMA; HUMAN; MALE; MEDULLOBLASTOMA; NEUROBLASTOMA; NEUROECTODERM TUMOR; OSTEOSARCOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PONTINE GLIOMA; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA; SOLID TUMOR; SYNOVIAL SARCOMA; TREATMENT RESPONSE; ADOLESCENT; ADULT; CLINICAL TRIAL; FOLLOW UP; HOSPITALIZATION; INFANT; META ANALYSIS (TOPIC); MORTALITY; MULTIMODALITY CANCER THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; NEWBORN; PRESCHOOL CHILD; PROGNOSIS; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; TIME; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; MALE; META-ANALYSIS AS TOPIC; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TIME FACTORS; YOUNG ADULT;

EID: 84924184219     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0000000000000237     Document Type: Article

References (40)

1. Balis F. The challenge of developing new therapies for childhood cancers. Oncologist. 1997;2:I-II.
2. Smith MA, Seibel NL, Altekruse SF, et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol. 2010;28:2625-2634.
3. Smith M, Bernstein M, Bleyer WA, et al. Conduct of phase I trials in children with cancer. J Clin Oncol. 1998;16:966-978.
4. Shah S, Weitman S, Langevin AM, et al. Phase I therapy trials in children with cancer. J Pediatr Hematol Oncol. 1998;20:431-438.
5. Lee DP, Skolnik JM, Adamson PC. Pediatric phase I trials in oncology: an analysis of study conduct efficiency. J Clin Oncol. 2005;23:8431-8841.
6. Kim A, Fox E, Warren K, et al. Characteristics and outcome of pediatric patients enrolled in phase I oncology trials. Oncologist. 2008;13:679-689.
7. Weitman S, Ochoa S, Sullivan J, et al. Pediatric phase II cancer chemotherapy trials: a pediatric oncology group study. J Pediatr Hematol Oncol. 1997;19:187-191.
8. Morgenstern DA, Hargrave D, Marshall LV, et al. Toxicity and outcome of children and adolescents participating in phase I/II trials of novel anticancer drugs: the royal marsden experience. J Pediatr Hematol Oncol. 2014;36:218-223.
9. Vassal G, Geoerger B, Morland B. Is the European pediatric medicine regulation working for children and adolescents with cancer?. Clin Cancer Res. 2013;19:1315-1325.
10. Lowis S, Lewis I, Elsworth A, et al. A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours. Br J Cancer. 2006;95:571-580.
11. Geoerger B, Doz F, Gentet J-C, et al. Phase I study of weekly oxaliplatin in relapsed or refractory pediatric solid malignancies. J Clin Oncol. 2008;26:4394-4400.
12. Geoerger B, Estlin EJ, Aerts I, et al. A phase I and pharmacokinetic study of plitidepsin in children with advanced solid tumours: an Innovative Therapies for Children with Cancer (ITCC) study. Eur J Cancer. 2012;48:289-296.
13. Geoerger B, Hargrave D, Thomas F, et al. Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro Oncol. 2011;13:109-118.
14. White-Koning M, Civade E, Geoerger B, et al. Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children. Clin Cancer Res. 2011;17:4862-4871.
15. Geoerger B, Aerts I, Casanova M, et al. Phase I/II study of LDE225, a Smoothened (Smo) antagonist, in pediatric patients with recurrent medulloblastoma or other solid tumors. J Clin Oncol. 2012;30. abstr e9519.
16. Pearson ADJ, McGregor L, Aerts I, et al. A phase I study of ridaforolimus (MK-8669) in pediatric patients with advanced solid tumors. J Clin Oncol. 2013;31. abstr e10027.
17. Frappaz D, Frederico S, Pearson A, et al. A phase I study of the anti-insulin like growth factor type 1 receptor antibody dalotuzumab in pediatric patients with advanced solid tumors. J Clin Oncol. 2013;31. abstr e10026.
18. Geoerger B, Vassal G, Doz F, et al. Dose finding and O6-Alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies. Br J Cancer. 2005;93:529-537.
19. Rubie H, Geoerger B, Frappaz D, et al. Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours. Eur J Cancer. 2010;46:2763-2770.
20. Vassal G, Giammarile F, Brooks M, et al. A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: a European cooperation of the Societe Francaise d'Oncologie Pediatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG). Eur J Cancer. 2008;44:2453-2460.
21. Rubie H, Chisholm J, Defachelles AS, et al. Phase II study of temozolomide in relapsed or refractory high-risk neuroblastoma: a joint Socie te Francaise des Cancers de l'Enfant and United Kingdom Children Cancer Study Group-New Agents Group Study. J Clin Oncol. 2006;24:5259-5264.
22. Geoerger B, Morland B, Ndiaye A, et al. Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium. Eur J Cancer. 2009;45: 2342-2351.
23. Petain A, Kattygnarath D, Azard J, et al. Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clin Cancer Res. 2008;14:7102-7109.
24. Geoerger B, Kieran MW, Grupp S, et al. Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma. Eur J Cancer. 2012;48: 253-262.
25. Pappo AS, Patel SR, Crowley J, et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol. 2011;29:4541-4547.
26. Juergens H, Daw NC, Geoerger B, et al. Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol. 2011;29:4534-4540.
27. Grill J, Lowis S, Frappaz D, et al. Phase II study of the combination of cisplatin plus temozolomide in malignant glial tumours in children and adolescents at diagnosis or in relapse. J Clin Oncol. 2007;25. abstr e9543.
28. Minard-Colin V, Ichante J-L, Nguyen L, et al. Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: good tolerance profile and efficacy in rhabdomyosarcoma-A report from the Socie te Francaise des Can. Eur J Cancer. 2012;48:2409-2416.
29. Geoerger B, Chisholm J, Le Deley M-C, et al. Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: an innovative therapy for children with Cancer European Consortium Study. Eur J Cancer. 2011;47:230-238.
30. Hargrave D, Geoerger B, Frappaz D, et al. A phase II singlearm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study. J Neurooncol. 2013;113:127-134.
31. Grill J, Geoerger B, Gesner L, et al. Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study. Neuro Oncol. 2013;15: 1236-1243.
32. Di Giannatale A, Dias-Gastellier N, Devos A, et al. Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study. Eur J Cancer. 2014;50:170-177.
33. Paoletti X, Geoerger B, Doz F, et al. A comparative analysis of paediatric dose-finding trials of molecularly targeted agent with adults' trials. Eur J Cancer. 2013;49:2392-2402.
34. Arkenau H-T, Olmos D, Ang JE, et al. Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. Br J Cancer. 2008;98:1029-1033.
35. Wheler J, Tsimberidou AM, Hong D, et al. Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience. Clin Cancer Res. 2012;18: 2922-2929.
36. Arkenau H-T, Olmos D, Ang JE, et al. 90-Days mortality rate in patients treated within the context of a phase-I trial: how should we identify patients who should not go on trial?. Eur J Cancer. 2008;44:1536-1540.
37. Bachelot T, Ray-Coquard I, Catimel G, et al. Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. Ann Oncol. 2000;11:151-156.
38. Estlin EJ, Cotterill S, Pratt CB, et al. Phase I trials in pediatric oncology: perceptions of pediatricians from the United Kingdom Children's Cancer Study Group and the Pediatric Oncology Group. J Clin Oncol. 2000;18:1900-1905.
39. Weinfurt KP, Castel LD, Li Y, et al. The correlation between patient characteristics and expectations of benefit from Phase I clinical trials. Cancer. 2003;98:166-175.
40. Italiano A, Massard C, Bahleda R, et al. Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy. Ann Oncol. 2008;19:787-792.